2006 annual general meeting dr mark treherne non executive chairman mr david mcauliffe director 1 corporate overview neurodiscovery is a biopharmaceutical service provider and clinical development company targeting neuropathic pain management s lead products nsl 043 101 consistently demonstrates results in several gold standard models of planned to commence phase i trial 2007 ii 2008 due complete human efficacy trials asx code ndl share price 0 17 market cap 6 4m cash 9m shares on issue 38 016 m 3 157 options shareholders the university warwick 9 13 7 22 fei yue zhao 98 prof spanswick kevin lee margaret livingston 47 top twenty 70 addressing unmet needs events should significant re rating enter during with potential positive mid approval late second half increasing revenues from specialist business will support programme expenses likely
